Ironwood Pharmaceuticals, Inc.IRWDNASDAQ
LOADING
|||

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
29 analysts·High coverage
38%
Rating Distribution
Strong Buy
00%
Buy
1138%
Hold
1552%
Sell
310%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see modest upside — consensus target 9% higher.

Bear Case
$5.00
+2%
Consensus
$5.35
+9%
Bull Case
$5.70
+17%
Price Range29 analysts
Low
Consensus
High
$5.00
$5.70
Current Target
Current Price
$4.89
Upside to Target
$0.46

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 5, 2026Craig-Hallum
Craig-Hallum upgrades Ironwood to Buy following 2026 guidance
Target:$5.70
+33.5%from $4.27
Jan 4, 2026Wells Fargo
Ironwood price target raised to $5 from $3 at Wells Fargo
Target:$5.00
+17.1%from $4.27
Nov 26, 2025Craig-Hallum
Ironwood price target raised to $3.80 from $1.70 at Craig-Hallum
Target:$3.80
-0.7%from $3.83
Apr 14, 2025Leerink Partners
Ironwood price target lowered to $1 from $3 at Leerink
Target:$1.00
+54.3%from $0.65
Jan 31, 2025Wells Fargo
Ironwood price target lowered to $7 from $12 at Wells Fargo
Target:$7.00
+199.1%from $2.34
Sep 9, 2024Leerink Partners
Ironwood initiated with a Market Perform at Leerink
Target:$5.00
+10.9%from $4.51
Aug 9, 2024Wells Fargo
Ironwood price target lowered to $12 from $14 at Wells Fargo
Target:$12.00
+196.3%from $4.05
May 22, 2024Piper Sandler
Piper Sandler Reiterates Overweight Rating on Ironwood Pharmaceuticals (IRWD)
Target:$18.00
+163.9%from $6.82
May 22, 2024Wells Fargo
Wells Fargo Reiterates Overweight Rating on Ironwood Pharmaceuticals (IRWD)
Target:$14.00
+106.5%from $6.78
Apr 22, 2022Piper Sandler
Ironwood Pharmaceuticals (IRWD) Stock: Why The Price Increased 3.4% Today
Target:$16.00
+31.4%from $12.18